What is⁣ Pin1 and Why is it important in Pancreatic ⁢Cancer?

Pin1 is an⁣ oncogenic enzyme, meaning it promotes cancer ⁣growth. It is frequently overexpressed in various tumors, including pancreatic cancer. Its role involves stabilizing other proteins that drive tumor growth and survival.Conventional cancer therapies often focus on blocking the activity of these proteins. However, this approach can lead to resistance as cancer cells adapt. The new research focuses on a different strategy:⁤ degrading Pin1 itself, effectively removing it from the system.

the “Molecular Crowbar” Approach

Researchers at the University of California, Riverside⁢ (UCR) developed a ⁤novel strategy to ⁢degrade⁢ Pin1. They designed compounds that act as a ⁣”molecular crowbar,” binding to Pin1 and destabilizing its structure.this destabilization leads to the enzyme’s ⁣degradation within the cell.

This approach is ‍significant as it doesn’t just target ⁤cancer cells directly.It also addresses tumor-supporting cells, such as cancer-associated fibroblasts and macrophages, where Pin1 is also active. This is crucial because the fibrous⁣ tumor microenvironment in pancreatic cancer often contributes to⁤ treatment resistance.

Collaboration Between UCR and City ‍of Hope

The UCR team, led by Maurizio pellecchia, collaborated with a team at City⁢ of Hope, led by Mustafa Raoof, to further test these Pin1 degraders in pancreatic and ⁢gastrointestinal cancers. The goal is to develop a new class of therapeutics ⁤that can “remove” harmful proteins rather ⁢than simply ⁣blocking them.

This collaboration was facilitated by a⁣ shared U54⁢ grant from the National cancer Institute (NCI), part of the‍ National institutes of Health (NIH).

Key Findings and⁢ Potential Benefits

The research builds upon previous work ‍where UCR researchers successfully developed the initial Pin1 degradation strategy. this latest phase focuses on validating the approach in more‍ complex⁢ models of pancreatic and gastrointestinal cancers.

Degrading Pin1 offers several potential advantages:

• Overcoming ⁤Resistance: By removing the⁤ enzyme, the approach may bypass resistance mechanisms that⁣ develop‍ with traditional inhibitors.
• Targeting the Tumor Microenvironment: Addressing Pin1 in supporting cells could disrupt⁣ the environment ⁢that fuels tumor growth.
• Novel ⁣therapeutic Class: This‍ research contributes to a growing field of “degrader” therapeutics, offering a new way to combat cancer.

Timeline and Next Steps

2023: UCR researchers develop the initial “molecular crowbar” strategy to degrade Pin1.

Present: Collaboration between ⁢UCR and City of Hope ⁣to test ⁣Pin1 degraders in pancreatic⁣ and gastrointestinal ⁤cancer models.

Future: Further preclinical studies, followed by potential clinical trials to evaluate ⁢the safety ‍and efficacy of these degraders in humans.